Anamorelin Fumarate is primarily used in the treatment of cancer-related cachexia, a condition characterized by severe weight loss and muscle wasting in patients with advanced malignancies. It works by stimulating appetite and promoting weight gain, particularly lean body mass, which helps improve the overall quality of life and physical strength in affected individuals. This compound is often administered to patients who have not responded adequately to dietary interventions or other supportive therapies. Its application is particularly significant in oncology, where maintaining body weight and muscle mass can enhance tolerance to cancer treatments and potentially improve survival outcomes.